Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Feb 11, 2015 5:37pm

185 Views

Post# 23419907

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:News Release Issued: Feb 10, 2015 (12:00pm MST)

Hi Jkj.

Can't help out on that. I just looked at the post and was pleasantly surprised. Hope the science people can help with an answer OR more importantly if RVX is on top of their game they should step up to the plate and explain it to their shareholders in terms of it's significance.

So if it is important RVX please let us know.

Have a great night.
Cheers
Toinv :)

Bullboard Posts

Changing Europe’s dependency on HREE from China